Home Cart Sign in  
Chemical Structure| 875337-44-3 Chemical Structure| 875337-44-3

Structure of MGCD-265 analog
CAS No.: 875337-44-3

Chemical Structure| 875337-44-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MGCD-265, an ATP-competitive inhibitor, can inhibit c-Met and VEGFR1, 2, 3 with IC50s of 1 nM and 3 nM, 3 nM, 4 nM, respectively. It also exhibits inhibition of Ron and Tie2.

Synonyms: MGCD-265

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MGCD-265 analog

CAS No. :875337-44-3
Formula : C26H20FN5O2S2
M.W : 517.60
SMILES Code : O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=CN(C)C=N4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=CC=C5
Synonyms :
MGCD-265
MDL No. :MFCD17779287
InChI Key :UFICVEHDQUKCEA-UHFFFAOYSA-N
Pubchem ID :24901704

Safety of MGCD-265 analog

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MGCD-265 analog

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    VEGFR1, IC50:3 nM

  • VEGFR3

    VEGFR3, IC50:4 nM

  • VEGFR2

    VEGFR2, IC50:3 nM

  • Tie-2

    Tie-2, IC50:7 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02954991 Carcinoma, Non-Small-Cell Lung Phase 2 Recruiting April 2019 -
NCT00679133 Advanced Malignancies Phase 1 Completed - United States, Michigan ... More >> Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Texas University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00975767 Advanced Malignancies, Non-sma... More >>ll Cell Lung Cancer Less << Phase 1 Terminated(The study was termi... More >>nated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2.) Less << - United States, Michigan ... More >> Barbara Ann Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Pennsylvania University of Pennsylvania Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 United States, Texas The University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 South Texas Accelerated Research Therapeutics, LLC San Antonio, Texas, United States, 78229 Less <<
NCT02117245 - Completed - Canada, Quebec ... More >> Algorithme Laval, Quebec, Canada Less <<
NCT02544633 Non-Small Cell Lung Cancer Phase 2 Active, not recruiting December 2018 -
NCT00697632 Advanced Cancer Phase 1 Active, not recruiting December 2018 United States, California ... More >> City of Hope Duarte, California, United States, 91010 UC Irvine Medical Center Orange, California, United States, 92868 UC San Diego San Diego, California, United States, 92093 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University, Alvin J. Siteman Cancer Center Saint Louis, Missouri, United States, 63110 United States, New York Columbia University, Herbert Irving Comprehensive Cancer Center New York, New York, United States, 10032 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Texas University of Texas, MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency, Vancouver Center Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T IE2 Korea, Republic of National Cancer Center Gyeonggi-do, Korea, Republic of, 410-769 Seoul National University Hosptial Seoul, Korea, Republic of, 110-744 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Yonsei University Health System, Severance Hospital Seoul, Korea, Republic of Less <<
NCT01930006 Advanced Malignancies Phase 1 Completed - United States, Kansas ... More >> Vince & Associates Clinical Research, Inc. Overland Park, Kansas, United States, 66212 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.66mL

1.93mL

0.97mL

19.32mL

3.86mL

1.93mL

References

 

Historical Records

Categories